NEW YORK – BostonGene on Tuesday said it is partnering with BeiGene to identify actionable tumor-based biomarkers in mantle cell lymphoma (MCL) to guide precision medicine treatment approaches.
The firms will investigate molecular drivers of resistance and response in MCL, which is associated with high rates of relapse and resistance to standard therapies. BostonGene will apply its foundation AI platform to analyze tumor-specific genomic alterations and immune microenvironment dynamics gleaned from whole-exome and RNA sequencing and high-depth hematological cancer panel data alongside clinical outcome information. Using the resulting comprehensive genomic, transcriptomic, and immunological profiles, the researchers will attempt to identify predictive and prognostic biomarker signatures of therapeutic response and disease progression.
The Waltham, Massachusetts-based company has inked a number of similar collaboration deals recently. In August 2024, it teamed up with Takeda to identify molecular drivers and predictive markers in immune-oncology clinical research using its AI-driven multiomic capabilities. The company has also partnered with academic research centers including the Sylvester Comprehensive Cancer Center and the Icahn School of Medicine at Mount Sinai to leverage its AI platform for precision medicine studies.